The availability of monoclonal antibodies that target the MYC, BCL2 and BCL6 protein, respectively, has been shown to predict the corresponding gene rearrangements by our and other independent groups and has been validated for use FFPE tissues [44], allowing for the study of large series of archived DLBCL samples for the protein expressions by IHC. Here, BCL2 is linked to diffuse large B-cell lymphoma.